AstraZeneca

Innovative public-private collaboration to tackle antibiotic research

Friday, May 25, 2012 01:05 PM

AstraZeneca and GlaxoSmithKlinehas welcomed the launch of a pioneering approach to antibiotic research in Europe that will see pharmaceutical and biotechnology companies working alongside public partners to tackle the rising threat from antibiotic resistance and address some of the key barriers to the development of effective antibiotics.

More... »

Creabilis appoints Simon Russell as chief business officer

Friday, May 4, 2012 04:43 PM

Creabilis, a European biotech specializing in the development of treatments for dermatology, inflammation and pain, has appointed Simon Russell as chief business officer.

More... »

NIH launches collaborative program to spur therapeutic development

Friday, May 4, 2012 08:02 AM

The National Institutes of Health (NIH) has unveiled a collaborative program, Discovering New Therapeutic Uses for Existing Molecules, that will match researchers with a selection of pharmaceutical industry compounds to help scientists explore new treatments for patients.

More... »

Axerion, AZ collaborate on biologic treatment approach for Alzheimer's

Wednesday, May 2, 2012 10:06 AM

Axerion Therapeutics, a private Connecticut-based biotech, and MedImmune, the global biologics arm of AstraZeneca, have entered into a research collaboration and sublicense arrangement to develop and commercialize a biologic approach for the treatment of Alzheimer's disease.

More... »

AstraZeneca’s CEO Brennan to retire

Friday, April 27, 2012 11:30 AM

Global biopharmaceutical company AstraZeneca has announced that CEO and board member David Brennan has decided to retire, effective June 1, 2012.

More... »

AZ to acquire Ardea for $1 billion

Monday, April 23, 2012 10:42 AM

Global biopharmaceutical company AstraZeneca has agreed to acquire Ardea Bioscience, a San Diego-based biotechnology company focused on the development of small-molecule therapeutics.

More... »

Report: Pharmaceutical market grew by 5.3% in 2011

Friday, April 20, 2012 12:29 PM

Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, found that in 2011, the global pharmaceutical market, in dollar terms, benefitted significantly from positive currency effects.

More... »

AstraZeneca and Conformetrix form collaboration

Monday, April 16, 2012 10:00 AM

Through a newly-formed research collaboration, Conformetrix, a company focused on optimizing drug discovery and design, will apply its proprietary NMR-based technology across AstraZeneca’s pre-clinical therapeutic pipeline to enhance lead discovery and hit identification.

More... »

Amgen, AstraZeneca to develop and commercialize inflammation portfolio

Monday, April 2, 2012 04:38 PM

Amgen and AstraZeneca have agreed to jointly develop and commercialize five monoclonal antibodies from Amgen's clinical inflammation portfolio (AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab (AMG 827)).

More... »

AZ, BioFocus, Argenta collaborate on respiratory and inflammatory diseases

Thursday, March 15, 2012 06:02 AM

Galapagos’ service companies, BioFocus and Argenta, have entered into a multi-year collaboration agreement with AstraZeneca to find new compounds against key targets in respiratory and inflammatory diseases.

More... »